Mitsubishi UFJ Asset Management UK Ltd. Reduces Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Mitsubishi UFJ Asset Management UK Ltd. decreased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 96.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 300 shares of the medical equipment provider’s stock after selling 9,500 shares during the quarter. Mitsubishi UFJ Asset Management UK Ltd.’s holdings in Lantheus were worth $27,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LNTH. Wilmington Savings Fund Society FSB purchased a new stake in Lantheus in the third quarter worth $25,000. Signaturefd LLC lifted its position in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares during the period. UMB Bank n.a. lifted its position in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 126 shares during the period. Kathleen S. Wright Associates Inc. purchased a new position in Lantheus during the third quarter valued at $51,000. Finally, GAMMA Investing LLC lifted its position in Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after buying an additional 146 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Buying and Selling

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

LNTH has been the subject of several recent research reports. JMP Securities reissued a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. The Goldman Sachs Group initiated coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. Truist Financial reaffirmed a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Finally, StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Stock Performance

NASDAQ LNTH opened at $94.05 on Wednesday. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89. The stock has a 50-day moving average of $90.05 and a 200 day moving average of $100.33. The company has a market capitalization of $6.54 billion, a price-to-earnings ratio of 15.65 and a beta of 0.46.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.